|
시장보고서
상품코드
2117036
분자 스위치 표적 치료 시장 : 용도별, 치료 대상별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Molecular Switch Targeting Therapies Market, By Application Area, By Target Therapy, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
분자 스위치 표적 치료 시장 규모는 2025년에 8억 3,040만 달러로 평가되며, 2026년부터 2033년까지 CAGR 13.5%로 확대될 것으로 전망됩니다.
분자 스위치 표적 치료는 유전자 변형된 스위치를 활용하여, 약물 투여 후 세포 내에서의 치료 기능, 지속성, 결합성 및 안전성 프로파일을 제어하는 혁신적인 의약품입니다. 분자 스위치 시장은 전환 가능한 CAR-T 구축체, 약물 결합형 수용체, 어댑터, 유도형 안전 스위치 및 유전자 치료 플랫폼으로 구성되어 있습니다. 이 기술은 종양학, 자가면역 질환 및 염증성 질환, 신경과학, 그리고 특정 재생의학 분야 등 광범위한 질환을 대상으로 합니다.
각 기업은 치료 효과를 미세하게 조정할 수 있는 유사한 화학 스위치 개발에 주력하고 있습니다. 한편, 분자 스위치 기술의 주요 과제는 이러한 스위치를 안정적으로 제조하고 그 성능을 임상적으로 입증하는 것입니다. 2025년, Calibr사의 치료 후보 물질인 CLBR001 및 스위치 플랫폼 SWI019가 임상시험 단계에 진입했습니다. 이는 분자 스위치 자체가 치료제가 되어가고 있음을 보여줍니다. 따라서 제어성은 더 이상 부수적인 요소가 아니라, 혁신적인 세포·유전자 치료제의 중요한 구성요소가 되었습니다.
분자 스위치 표적 치료시장 - 시장 역학
프로그래밍 가능한 치료 제어 기능이 생체의약제의 유용성을 확대하고 있습니다
개발자들이 생체 의약품에 대한 보다 정교한 제어력을 요구함에 따라, 투여 후 치료 활성을 조절하는 능력은 점점 더 중요해지고 있습니다. 기존의 CAR-T 요법은 이식 후에도 생존 능력과 치료 활성을 유지하지만, 지속적인 면역 반응이 바람직하지 않은 경우에는 문제가 됩니다. 분자 스위치는 스위치의 활성화를 투여되는 분자와 연동시킴으로써 추가적인 제어를 가능하게 하며, 임상의가 치료량을 미세 조정하고 치료용 세포의 완전한 제거를 피할 수 있게 해줄 가능성이 있습니다. 이 메커니즘은 암 치료에 비해 위험과 이점의 균형이 더 복잡하고 치료 주기도 긴 자가면역 질환의 치료에 최적입니다. Calibr사는 2025년부터 4가지 자가면역질환을 대상으로 한 1상 임상시험 프로그램을 시작했습니다. 이를 통해 해당 기술의 적용 범위를 암 이외의 분야로 확대함과 동시에, 프로그래밍 가능한 제어 기술이 지닌 가치를 부각시켜 CAR-T 요법의 적용 범위를 더욱 넓히고, 모든 질환 영역으로 확장할 가능성을 보여주고 있습니다.
분자 스위치 표적 치료 시장 - 지역별 인사이트
북미는 전문적인 임상 센터, 세포 공학 전문 지식, 벡터 제조 인프라, 그리고 세포·유전자 치료에 관한 규제 경험이 존재하기 때문에 분자 스위치 표적 치료 분야에서 확고한 입지를 유지하고 있습니다. 동시에 미국에서는 유전자 변형 면역 세포 치료법의 신속한 개발 및 상용화 기회가 제공되고 있습니다. 2025년, FDA는 변연대 림프종 치료제로 ‘브레이안지(Breyanzi)’를 승인했으며, 이로 인해 CAR-T 세포 요법의 적용 대상이 되는 림프종의 범위가 확대되었습니다. 따라서 현재의 임상 상황은 차세대 전환 가능한 치료제의 개발과 차별화를 위한 기반을 마련하고 있습니다. 그 결과, 북미는 세포 치료제에 대한 프로그래밍 가능한 제어 접근 방식을 도입하는 데 있어 중요한 지역이 되었습니다.
유럽은 종합적인 규제 체계, 첨단 연구 인프라, 그리고 분자 스위치형 치료제 개발을 위한 강력한 중개 연구 환경을 특징으로 합니다. EMA(유럽의약품청)의 첨단치료법위원회는 복잡한 세포 및 유전자 치료법을 평가하여, 개발자가 품질, 제조 공정, 생물학적 메커니즘 및 임상 적응증에 관한 적절한 증거를 제시할 수 있도록 보장하고 있습니다. 2025년에는 미충족 의료 수요가 높은 의약품 개발자에게 과학적 및 규제적 지원을 제공하는 EMA의 PRIME(우선 의약품) 제도에 16개의 의약품이 선정되었습니다. PRIME 지정이 분자 스위치 치료법에 특화된 것은 아니지만, 이 제도는 복잡한 질환 치료를 위한 혁신적인 접근 방식을 추진하려는 해당 지역의 노력을 잘 보여줍니다. 그 결과, 세포 기반 프로그래밍 가능한 치료제에 대해 유럽은 높은 수준의 과학적 전문 지식과 결합된 종합적인 규제 환경을 제공하고 있습니다.
목차
제1장 분자 스위치 표적 치료 시장 개요
제2장 주요 요약
제3장 분자 스위치 표적 치료 주요 시장 동향
제4장 분자 스위치 표적 치료 산업 분석
제5장 분자 스위치 표적 치료 시장 : 높아지는 지정학적 긴장의 영향
제6장 분자 스위치 표적 치료 시장 구도
제7장 분자 스위치 표적 치료 시장 : 적용 분야별
제8장 분자 스위치 표적 치료 시장 : 표적 치료별
제9장 분자 스위치 표적 치료 시장 : 최종사용자별
제10장 분자 스위치 표적 치료 시장 : 지역별
제11장 주요 벤더 분석 : 분자 스위치 표적 치료 산업
제12장 AnalystView의 전방위 전망
KSM 26.08.26Molecular Switch Targeting Therapies Market size was valued at US$ 830.4 Million in 2025, expanding at a CAGR of 13.5% from 2026 to 2033.
Molecular switch targeting therapies are innovative medicinal products that utilize engineered switches to control therapeutic function, persistence, engagement, and safety profiles in cells after drug administration. The molecular switch market consists of switchable CAR-T constructs, drug-coupled receptors, adapters, inducible safety switches, and gene-therapy platforms. It targets a wide range of diseases, including oncology, autoimmune and inflammatory disorders, neuroscience, and certain regenerative medicine conditions.
Companies work on similar chemical switches that allow for fine-tuning of therapy potency. At the same time, the key challenges for molecular switch technologies are the consistent production of these switches and the clinical validation of their performance. In 2025, Calibr's therapeutic candidate CLBR001 and switch platform SWI019 entered the clinic, indicating that molecular switches are becoming therapeutics themselves. Thus, controllability is no longer an afterthought but rather a critical component of innovative cell and gene medicines.
Molecular Switch Targeting Therapies Market- Market Dynamics
Programmable Therapeutic Control Is Expanding the Utility of Living Medicines
The ability to regulate therapeutic activity after administration is becoming increasingly important as developers seek greater control over living medicines. Existing CAR-T therapies can remain viable and therapeutically active post-transplant, which poses a problem when continued immune engagement is unwanted. Molecular switches give added control by linking activation of a switch to an administered molecule, potentially enabling clinicians to titrate therapy and avoid complete elimination of therapeutic cells. This mechanism is ideally suited to autoimmune diseases-a context wherein treatment entails more risk-benefit and longer treatment cycles than oncology Target Therapys. Calibr developed a Phase 1 program across four autoimmune indications starting in 2025, expanding on the technology into this non-oncologic field and highlighting the value proposition for programmable control to extend CAR-T Target Therapys further up the chain into an entire spectrum of diseases.
Molecular Switch Targeting Therapies Market- Geographical Insights
North America maintains a strong position in molecular-switch targeting therapies due to the presence of specialized clinical centers, cell engineering expertise, vector manufacturing infrastructure, and regulatory experience with cellular and gene therapies. At the same time, the U.S. offers opportunities for rapid development and commercialization of engineered immune-cell therapeutics. In 2025, the FDA approved Breyanzi for the treatment of marginal zone lymphoma, thereby expanding the range of lymphomas for CAR-T cell therapy. Thus, the current clinical landscape creates the basis for the development and differentiation of the next-generation switchable therapeutics. As a result, North America has become an important region for implementing programmable control approaches to cellular therapeutics.
Europe is characterized by a comprehensive regulatory framework, advanced research infrastructure, and a strong translational environment for developing molecular-switch therapeutics. The EMA's Advanced Therapies Committee evaluates complex cell and gene therapies, ensuring that developers generate relevant evidence on quality, manufacturing processes, biological mechanisms, and clinical indications. In 2025, 16 medicines were selected for the EMA's PRIME (Priority Medicines) scheme, which provides scientific and regulatory support to developers of medicines with high unmet clinical needs. Although the PRIME designation does not specifically focus on molecular-switch therapies, this scheme highlights the region's commitment to promoting innovative approaches to treating complex diseases. As a result, for cell-based programmable therapeutics, Europe offers a comprehensive regulatory environment combined with high-level scientific expertise.
Molecular Switch Targeting Therapies Market- Competitive Landscape:
The competition to develop cellular therapies has shifted towards the degree of control over treatment by engineers and is no longer focused on the intricacies of CAR design. Thus, firms are investing heavily in engineering cells where control over activation is achieved through adapted T-cell engagement, receivable signaling to drug-like molecules, inducible safety switches, persistence regulation, vector construction, and manufacturing processes that facilitate the preservation of critical quality attributes. Cell therapy developers with substantial clinical and regulatory expertise have advantages over those that only specialize in biotech, but the latter can profit from investing in switch technologies and partnerships. In 2025, Breyanzi extended the list of approved cancers in the US to five, indicating the value of cellular therapy producers that utilize validated CAR-T platforms. Moreover, it can be expected that cellular therapy producers will gain advantages by combining robustness in therapeutic cell types with external control mechanisms and individual adjustments.
Recent Developments:
In April 2025, Calibr announced the initiation of a Phase I clinical trial evaluating the combination of the switchable CAR-T platform CLBR001 and SWI019 to treat four autoimmune diseases.
In December 2025, Bristol Myers Squibb's Breyanzi was approved by the FDA for the treatment of patients with relapsed or refractory marginal zone lymphoma.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- aceRNA Technologies
- Autolus Therapeutics plc
- Bellicum Pharmaceuticals, Inc.
- Cellectis S.A.
- Kiromic BioPharma, Inc.
- panCELLa Inc.
- Precigen, Inc.
- Sana Biotechnology, Inc.
- Sangamo Therapeutics, Inc.
- Editas Medicine, Inc.
- Merck & Co., Inc.
- Bristol Myers Squibb
- AbbVie Inc.
- Sanofi
- Regeneron Pharmaceuticals, Inc.
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY APPLICATION AREA- MARKET ANALYSIS, 2020 - 2033
- Management of Treatment-Related Toxicity
- Regulation of Gene Expression
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY TARGET THERAPY- MARKET ANALYSIS, 2020 - 2033
- CAR-T Cell Therapy
- Gene Therapy
- Other Cell & Gene Therapies
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Biotechnology Companies
- Pharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Molecular Switch Targeting Therapies Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.2. Competitive Insights
3. Molecular Switch Targeting Therapies Key Market Trends
- 3.1. Molecular Switch Targeting Therapies Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Molecular Switch Targeting Therapies Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Molecular Switch Targeting Therapies Market Opportunities
- 3.4. Molecular Switch Targeting Therapies Market Future Trends
4. Molecular Switch Targeting Therapies Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Molecular Switch Targeting Therapies Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Molecular Switch Targeting Therapies Market Landscape
- 6.1. Molecular Switch Targeting Therapies Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Molecular Switch Targeting Therapies Market - By Application Area
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Application Area, 2025 & 2033 (%)
- 7.1.2. Autoimmune and Inflammatory Disorders
- 7.1.3. Oncology
- 7.1.4. Neurological Disorders
- 7.1.5. Others
8. Molecular Switch Targeting Therapies Market - By Target Therapy
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Target Therapy, 2025 & 2033 (%)
- 8.1.2. CAR-T Cell Therapy
- 8.1.3. Gene Therapy
- 8.1.4. Other Cell & Gene Therapies
9. Molecular Switch Targeting Therapies Market - By End User
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
- 9.1.2. Biotechnology Companies
- 9.1.3. Pharmaceutical Companies
- 9.1.4. Academic & Research Institutes
- 9.1.5. Contract Research Organizations (CROs)
- 9.1.6. Others
10. Molecular Switch Targeting Therapies Market- By Geography
- 10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 10.2. North America
- 10.2.1. Overview
- 10.2.2. Molecular Switch Targeting Therapies Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.2.7. U.S.
- 10.2.7.1. Overview
- 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.7.3. U.S. Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.2.7.4. U.S. Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.2.8. Canada
- 10.2.8.1. Overview
- 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.8.3. Canada Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.2.8.4. Canada Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3. Europe
- 10.3.1. Overview
- 10.3.2. Molecular Switch Targeting Therapies Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.7. Germany
- 10.3.7.1. Overview
- 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.7.3. Germany Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.7.4. Germany Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.8. UK
- 10.3.8.1. Overview
- 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.8.3. UK Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.8.4. UK Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.9. France
- 10.3.9.1. Overview
- 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.9.3. France Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.9.4. France Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.10. Italy
- 10.3.10.1. Overview
- 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.10.3. Italy Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.10.4. Italy Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.11. Spain
- 10.3.11.1. Overview
- 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.11.3. Spain Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.11.4. Spain Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.12. The Netherlands
- 10.3.12.1. Overview
- 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.12.3. The Netherlands Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.12.4. The Netherlands Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.13. Sweden
- 10.3.13.1. Overview
- 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.13.3. Sweden Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.13.4. Sweden Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.14. Russia
- 10.3.14.1. Overview
- 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.14.3. Russia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.14.4. Russia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.15. Poland
- 10.3.15.1. Overview
- 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.15.3. Poland Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.15.4. Poland Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.16. Denmark
- 10.3.16.1. Overview
- 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.16.3. Denmark Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.16.4. Denmark Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.17. Rest of Europe
- 10.3.17.1. Overview
- 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.17.3. Rest of the Europe Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.3.17.4. Rest of the Europe Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Molecular Switch Targeting Therapies Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.7. China
- 10.4.7.1. Overview
- 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.7.3. China Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.7.4. China Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.8. India
- 10.4.8.1. Overview
- 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.8.3. India Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.8.4. India Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.9. Japan
- 10.4.9.1. Overview
- 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.9.3. Japan Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.9.4. Japan Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.10. South Korea
- 10.4.10.1. Overview
- 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.10.3. South Korea Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.10.4. South Korea Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.11. Australia
- 10.4.11.1. Overview
- 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.11.3. Australia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.11.4. Australia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.12. Indonesia
- 10.4.12.1. Overview
- 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.12.3. Indonesia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.12.4. Indonesia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.13. Thailand
- 10.4.13.1. Overview
- 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.13.3. Thailand Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.13.4. Thailand Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.14. Philippines
- 10.4.14.1. Overview
- 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.14.3. Philippines Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.14.4. Philippines Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.15. Taiwan
- 10.4.15.1. Overview
- 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.15.3. Taiwan Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.15.4. Taiwan Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.16. Vietnam
- 10.4.16.1. Overview
- 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.16.3. Vietnam Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.16.4. Vietnam Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.17. Rest of APAC
- 10.4.17.1. Overview
- 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.17.3. Rest of APAC Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.4.17.4. Rest of APAC Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Molecular Switch Targeting Therapies Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.7. Brazil
- 10.5.7.1. Overview
- 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.7.3. Brazil Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.5.7.4. Brazil Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.8. Mexico
- 10.5.8.1. Overview
- 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.8.3. Mexico Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.5.8.4. Mexico Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.9. Argentina
- 10.5.9.1. Overview
- 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.9.3. Argentina Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.5.9.4. Argentina Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.10. Colombia
- 10.5.10.1. Overview
- 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.10.3. Colombia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.5.10.4. Colombia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.11. Rest of LATAM
- 10.5.11.1. Overview
- 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.11.3. Rest of LATAM Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.5.11.4. Rest of LATAM Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Molecular Switch Targeting Therapies Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.7. Saudi Arabia
- 10.6.7.1. Overview
- 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.7.3. Saudi Arabia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.7.4. Saudi Arabia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.8. UAE
- 10.6.8.1. Overview
- 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.8.3. UAE Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.8.4. UAE Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.9. Israel
- 10.6.9.1. Overview
- 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.9.3. Israel Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.9.4. Israel Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.10. Turkey
- 10.6.10.1. Overview
- 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.10.3. Turkey Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.10.4. Turkey Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.11. Algeria
- 10.6.11.1. Overview
- 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.11.3. Algeria Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.11.4. Algeria Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.12. Egypt
- 10.6.12.1. Overview
- 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.12.3. Egypt Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.12.4. Egypt Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.13. Iran
- 10.6.13.1. Overview
- 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.13.3. Iran Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.13.4. Iran Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.14. Qatar
- 10.6.14.1. Overview
- 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.14.3. Qatar Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.14.4. Qatar Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.15. Rest of MEA
- 10.6.15.1. Overview
- 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.15.3. Rest of MEA Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
- 10.6.15.4. Rest of MEA Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
- 10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Molecular Switch Targeting Therapies Industry
- 11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
- 11.2. Company Profiles
- 11.2.1. aceRNA Technologies
- 11.2.2. Autolus Therapeutics plc
- 11.2.3. Bellicum Pharmaceuticals, Inc.
- 11.2.4. Cellectis S.A.
- 11.2.5. Kiromic BioPharma, Inc.
- 11.2.6. panCELLa Inc.
- 11.2.7. Precigen, Inc.
- 11.2.8. Sana Biotechnology, Inc.
- 11.2.9. Sangamo Therapeutics, Inc.
- 11.2.10. Editas Medicine, Inc.
- 11.2.11. Merck & Co., Inc.
- 11.2.12. Bristol Myers Squibb
- 11.2.13. AbbVie Inc.
- 11.2.14. Sanofi
- 11.2.15. Regeneron Pharmaceuticals, Inc.
- 11.2.16. Others
12. 360 Degree AnalystView
13. Appendix
- 13.1. Research Methodology
- 13.2. References
- 13.3. Abbreviations
- 13.4. Disclaimer
- 13.5. Contact Us
